Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE:JNJ) reported updated Phase 1/1b CHRYSALIS-2 data for RYBREVANT plus LAZCLUZE as first-line therapy in atypical EGFR-mutated advanced NSCLC.
Median overall survival reached 41.0 months (~3.5 years), with three- and four-year overall survival rates of 55% and 46%, and a previously reported objective response rate of 57%.
Clinical activity and treatment duration were consistent across multiple atypical EGFR mutation subgroups, and 41% of patients stayed on RYBREVANT for ≥2 years. Safety findings were in line with earlier reports, with mostly Grade 1–2 adverse events and no new safety signals.
Johnson & Johnson (NYSE: JNJ) reported Phase 3 MajesTEC-9 results showing TECVAYLI® (teclistamab-cqyv) improved progression-free survival and overall survival versus standard regimens in relapsed/refractory multiple myeloma after 1–3 prior therapies.
TECVAYLI® cut risk of progression or death by 71% and death by 40%, with 65.9% achieving complete response or better, and has been submitted for regulatory review as early as second-line therapy.
Johnson & Johnson (NYSE: JNJ) received FDA approval for a supplemental Biologics License Application expanding the TREMFYA (guselkumab) label in adults with active psoriatic arthritis.
The label now includes evidence for inhibition of progression of structural joint damage, supported by Phase 3b APEX data showing reduced joint symptoms and structural damage with no new safety signals. TREMFYA is described as the only IL-23 inhibitor with structural inhibition information in its PsA label.
Johnson & Johnson (NYSE: JNJ) will host an investor conference call at 8:30 a.m. ET on Wednesday, July 15 to review second-quarter results, led by CEO Joaquin Duato, CFO Joseph J. Wolk and VP Investor Relations Ryan Koors.
The live webcast, presentation materials and press release (available around 6:45 a.m. ET) can be accessed via www.investor.jnj.com. Telephone dial-in and replay options are provided for U.S. and international participants, with replay access available until 12:00 a.m. on July 29. Investors are also advised of the planned third-quarter earnings call on Tuesday, October 13, 2026.
Johnson & Johnson (NYSE: JNJ) released results from a global survey of 817 non–muscle-invasive bladder cancer patients and 802 urologists across six countries.
Findings show that more than 90% of patients receiving bladder removal or BCG report negative impacts on most life aspects, underscoring the need for treatments reflecting quality-of-life priorities.
Johnson & Johnson (NYSE: JNJ) announced the global launch of the Shockwave C2 Aero Coronary IVL Catheter, a next-generation intravascular lithotripsy device for treating calcified coronary artery disease. The catheter is designed for improved deliverability, lesion crossing and balloon repositioning in complex, tortuous coronary anatomy.
Shockwave C2 Aero maintains Shockwave IVL’s mechanism of action and safety profile, with two emitters delivering up to 240 Shockwaves to fracture hardened calcium while preserving soft tissue. According to Johnson & Johnson, it is now available in the U.S. and Japan, with Europe and Canada to follow.
Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Management will join a fireside chat at 10:00 a.m. ET, available via live audio webcast and later replay on the J&J investor website.
Johnson & Johnson (NYSE: JNJ) will present 18 abstracts featuring new and encore data from its neuropsychiatry portfolio at the APA and ASCP 2026 meetings.
Highlights include Phase 3 data for CAPLYTA, seltorexant, SPRAVATO, and guidance on long-acting injectables in schizophrenia, MDD, TRD, and insomnia symptoms.
Johnson & Johnson (NYSE: JNJ) launched Generation Fine on May 7, 2026, a global campaign to encourage patients with major depressive disorder (MDD) to seek remission rather than accept being "fine."
Campaign is based on a global survey: nearly 4 in 5 patients doubt antidepressants will achieve remission; about 2 in 3 report ongoing symptoms. Generation Fine partners with Mental Health America, features patient stories and advocates, and provides resources to support conversations with healthcare providers.
Johnson & Johnson (NYSE: JNJ) reported Phase 2b DUET-UC and DUET-CD results for JNJ-4804, an investigational co-antibody targeting IL-23 and TNF-α. At Week 48 the JNJ-4804 high-dose group showed higher clinical remission and endoscopic response rates versus golimumab and numerically higher rates versus guselkumab in UC and CD.
JNJ will advance JNJ-4804 into Phase 3 DUET ENCORE-CD and DUET ENCORE-UC trials; safety was described as generally consistent with known monotherapy profiles.